Baker Bros. Advisors 13F: New $33M Stake in CMPS

Baker Bros. Advisors Enters COMPASS Pathways

Baker Bros. Advisors, a prominent investment firm known for its highly focused bets on the biotechnology and life sciences sectors, has established a brand-new position in COMPASS Pathways plc (NASDAQ: CMPS). According to the fund's latest Form 13F filing with the Securities and Exchange Commission, Baker Bros. acquired 2,344,720 shares of the mental health-focused biotech company.

This position is valued at approximately $33.18 million. Baker Bros. Advisors is widely watched by healthcare investors because of its deep scientific expertise and history of taking large, concentrated stakes in promising clinical-stage drug developers. This latest move shows the fund is turning its attention to the emerging field of psychedelic-assisted therapies.

A Significant New Biotech Holding

Since this is a brand-new position for Baker Bros. Advisors, there is no prior percentage change to report. The fund went from holding zero shares to owning 2,344,720 shares by the end of the reporting period. The filing reflects the fund's holdings as of the reporting date and may not represent the investor's current, real-time position in the market today. This move builds on a trend of institutional interest in the stock, following recent reports that RTW Investments also increased its own stake in the company.

COMPASS Pathways Stock Performance

On Sunday, the stock traded at $14.15. COMPASS Pathways has traded in a 52-week range of $4.88 to $15.87, placing its current price near the upper end of its yearly range. The stock is currently trading above its 50-day moving average of $13.26 and well above its 200-day moving average of $9.63. The company has a market capitalization of $2.08 billion but does not have a meaningful price-to-earnings ratio because it is not yet profitable.

Recent Earnings

COMPASS Pathways reported a negative earnings per share of -$3.79 for its latest period, with a net margin of 0.0% as it continues to fund its clinical trials. The company's return on equity came in at -3.19%. Investors are looking ahead to the next scheduled earnings announcement on November 3, 2026, to get updates on the company's cash runway and clinical progress.

Wall Street Analysts Weigh In

Several research firms have recently updated their outlooks on COMPASS Pathways. On August 7, 2026, HC Wainwright & Co. maintained its Buy rating on the stock, adjusting its price target to $65.00 from a previous $70.00. On August 6, 2026, Morgan Stanley maintained its Overweight rating and ticked its price target up to $18.00 from $17.00. On the same day, RBC Capital kept its Outperform rating with a $21.00 target, and B. Riley Securities maintained a Buy rating, raising its target to $22.00 from $17.00.

Earlier in the summer, Evercore ISI Group upgraded the stock to Outperform on July 8, 2026, raising its target to $21.00 from $8.00. Overall, the consensus among 16 analyst opinions is a strong buy, with a average price target of $23.75.

Inside COMPASS Pathways

COMPASS Pathways is a biotechnology company headquartered in London, United Kingdom. The company is dedicated to accelerating patient access to evidence-based innovation in mental health. Its lead program, COMP360, is a proprietary formulation of synthetic psilocybin that is currently undergoing Phase III clinical trials for treatment-resistant depression, alongside Phase II trials for post-traumatic stress disorder and anorexia nervosa.

What's Ahead for COMPASS Pathways plc

Investors interested in the psychedelic medicine space will want to monitor how Baker Bros. Advisors manages this position in subsequent quarters. Because 13F filings are backward-looking and released 45 days after the quarter ends, further filings and the upcoming earnings report on November 3, 2026, will be key to seeing if the fund continues to build its stake.